Strategies to enhance the therapeutic efficacy of antidepressants: Targeting residual symptoms

Expert Review of Neurotherapeutics

Volumn 9, Issue 7, 2009, Pages 975-984

  Kurian, Benji T ^a   Greer, Tracy L ^a   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antidepressant medication; Augmentation strategy; Depressive subtype; Major depressive disorder; Remission; Residual symptom

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHOLINESTERASE INHIBITOR; CITICOLINE; DONEPEZIL; DULOXETINE; ESZOPICLONE; FLUOXETINE; GABAPENTIN; GALANTAMINE; LIOTHYRONINE; LITHIUM; LORAZEPAM; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; PREGABALIN; PSYCHOSTIMULANT AGENT; RAMELTEON; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM;

AGITATED DEPRESSION; ANXIETY DISORDER; BIPOLAR DISORDER; CHRONIC PAIN; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIABETIC NEUROPATHY; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EVENING DOSAGE; FATIGUE; FIBROMYALGIA; HUMAN; INCIDENCE; INSOMNIA; IRRITABILITY; LONG TERM CARE; MAJOR DEPRESSION; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MORBIDITY; MORNING DOSAGE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PAIN; PATIENT SATISFACTION; POLYNEUROPATHY; PREVALENCE; PSYCHOTHERAPY; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; RISK; SOMATIZATION; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORKING MEMORY; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANXIETY; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; FATIGUE; HUMANS; RECURRENCE; SLEEP DEPRIVATION; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 67651030466     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.53     Document Type: Review

References (102)

1. Diagnostic and Statistical Manual of Mental Disorders - Text Revision. American Psychiatric Association, DC, USA (2000).
2. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 274(5288), 740-743 (1996).
3. Kessler RC, Akiskal HS, Ames M et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry 163(9), 1561-1568 (2006). (Pubitemid 44465756)
4. Rush AJ, Kraemer HC, Sackeim HA et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31(9), 1841-1853 (2006). •Defines remission as the standard treatment goal in major depressive disorder (MDD).
5. Paykel ES, Ramana R, Cooper Z et al. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 25(6), 1171-1180 (1995). •States the consequences of not achieving remission (i.e., residual symptoms) in MDD.
6. Olfson M, Marcus SC, Druss B et al. National trends in the outpatient treatment of depression. JAMA 287(2), 203-209 (2002). (Pubitemid 34251945)
7. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163(1), 28-40 (2006). ••Introduces the concept of measurement-based care as an objective method to achieve remission.
8. Keller MB, Gelenberg AJ, Hirschfeld RM et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J. Clin. Psychiatry 59(11), 598-607 (1998).
9. Keller MB, McCullough JP, Klein DN et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N. Engl. J. Med. 342(20), 1462-1470 (2000).
10. Hennings JM, Owashi T, Binder EB et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J. Psychiatr. Res. 43(3), 215-229 (2008).
11. Judd LL, Akiskal HS, Zeller PJ et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch. Gen. Psychiatry 57(4), 375-380 (2000).
12. Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am. J. Psychiatry 157(9), 1501-1504 (2000).
13. Rush AJ, Fava M, Wisniewski SR et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control. Clin. Trials 25(1), 119-142 (2004). (Pubitemid 38230109)
14. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother. Psychosom. 75(3), 139-153 (2006). •Reviews the current state of combination and augmentation treatments to enhance antidepressant efficacy.
15. National Institute of Mental Health Strategic Plan. US Department of Health and Human Services, National Institutes of Health, NIH Publication No. 08-6368, 22-23 (2008).
16. Altshuler LL, Bauer M, Frye MA et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatry 158(10), 1617-1622 (2001). (Pubitemid 32923653)
17. Bauer M, Bschor T, Kunz D et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am. J. Psychiatry 157(9), 1429-1435 (2000). (Pubitemid 30677135)
18. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J. Clin. Psychiatry 68(6), 935-940 (2007). (Pubitemid 47015495)
19. 3 augmentation following two failed medication treatments for depression: a STAR*D report. Am. J. Psychiatry 163(9), 1519-1530 (2006).
20. Ros S, Aguera L, de la Gandara J, Rojo JE, de Pedro JM. Potentiation strategies for treatment-resistant depression. Acta Psychiatr. Scand. Suppl. 36(428), 14-24, (2005).
21. Fava M, Thase ME, DeBattista C et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann. Clin. Psychiatry 19(3), 153-159 (2007). (Pubitemid 47345870)
22. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J. Clin. Psychiatry 60(Suppl. 22), 29-34 (1999).
23. Fava M, Alpert JE, Carmin CN et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol. Med. 34(7), 1299-1308 (2004). (Pubitemid 39517160)
24. Farabaugh A, Fava M, Mischoulon D et al. Relationships between major depressive disorder and comorbid anxiety and personality disorders. Compr. Psychiatry 46(4), 266-271 (2005). (Pubitemid 40814444)
25. Silverstone PH, von Studnitz E. Defining anxious depression: going beyond comorbidity. Can. J. Psychiatry 48(10), 675-680 (2003).
26. Kessler RC, Nelson CB, McGonagle KA et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br. J. Psychiatry Suppl. (30), 17-30 (1996).
27. Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am. J. Psychiatry 165(3), 342-351 (2008). (Pubitemid 351704490)
28. Dunner DL. Management of anxiety disorders: the added challenge of comorbidity. Depress. Anxiety 13(2), 57-71 (2001).
29. Greer TL, Trivedi MH. Comorbid depression and anxiety: characteristics, functional consequences, and treatment considerations. Univ. Virg. Sch. Med. Rep. Psychiatr. Disord. 2(2), 1-8 (2005).
30. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress. Anxiety 4(4), 160-168 (1996).
31. Harter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. Eur. Arch. Psychiatry Clin. Neurosci. 253(6), 313-320 (2003).
32. Papakostas GI, Petersen T, Hughes ME et al. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res. 126(3), 287-290 (2004). (Pubitemid 38626189)
33. Lydiard RB, Brawman-Mintzer O. Anxious depression. J. Clin. Psychiatry 59(Suppl. 18), 10-17 (1998).
34. Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim. Care Companion J. Clin. Psychiatry 10(3), 222-228 (2008).
35. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress. Anxiety 16(1), 4-13 (2002). (Pubitemid 34977120)
36. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress. Anxiety 18(2), 53-61 (2003). (Pubitemid 37175581)
37. Buysse DJ, Angst J, Gamma A et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 31(4), 473-480 (2008). (Pubitemid 351694269)
38. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J. Clin. Psychiatry 60(Suppl. 17), 28-31; discussion 46-48 (1999).
39. Nierenberg AA, Keefe BR, Leslie VC et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J. Clin. Psychiatry 60(4), 221-225 (1999).
40. Buckner JD, Bernert RA, Cromer KR, Joiner TE, Schmidt NB. Social anxiety and insomnia: the mediating role of depressive symptoms. Depress. Anxiety 25(2), 124-130 (2008).
41. Fava M. Daytime sleepiness and insomnia as correlates of depression. J. Clin. Psychiatry 65(Suppl. 16), 27-32 (2004).
42. Asnis GM, Chakraburtty A, DuBoff EA et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J. Clin. Psychiatry 60(10), 668-676 (1999). (Pubitemid 29503647)
43. Fava M, McCall WV, Krystal A et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol. Psychiatry 59(11), 1052-1060 (2006). (Pubitemid 43849658)
44. Becker PM. Treatment of sleep dysfunction and psychiatric disorders. Curr. Treat. Options Neurol. 8(5), 367-375 (2006).
45. Kupfer DJ. Pathophysiology and management of insomnia during depression. Ann. Clin. Psychiatry 11(4), 267-276 (1999).
46. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom. Med. 65(4), 528-533 (2003). (Pubitemid 36900246)
47. Deldin PJ, Phillips LK, Thomas RJ. A preliminary study of sleep-disordered breathing in major depressive disorder. Sleep Med. 7(2), 131-139 (2006).
48. O'Hara R, Schroder C. Unraveling the relationship of obstructive sleep-disordered breathing to major depressive disorder. Sleep Med. 7(2), 101-103 (2006). (Pubitemid 43300113)
49. Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J. Clin. Psychiatry 67(Suppl. 6), 9-15 (2006).
50. Preti A. Tomoxetine (Eli Lilly & Co). Curr. Opin. Investig. Drugs 3(2), 272-277 (2002).
51. Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J. Psychiatr. Res. 40(4), 370-373 (2006). (Pubitemid 43668989)
52. Michelson D, Adler LA, Amsterdam JD et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(4), 582-587 (2007). (Pubitemid 46663041)
53. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J. Clin. Psychiatry 66(1), 85-93 (2005).
54. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33(7), 1477-1502 (2008).
55. Veiel HO. A preliminary profile of neuropsychological deficits associated with major depression. J. Clin. Exp. Neuropsychol. 19(4), 587-603 (1997).
56. Coull JT. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog. Neurobiol. 55(4), 343-361 (1998).
57. Elliott R. Executive functions and their disorders. Br. Med. Bull. 65, 49-59 (2003).
58. Lezak M. Neuropsychological Assessment. Oxford University Press, NY, USA (1983).
59. Gohier B, Ferracci L, Surguladze SA et al. Cognitive inhibition and working memory in unipolar depression. J. Affect. Disord. 116(1-2), 100-105 (2009).
60. Rose EJ, Ebmeier KP. Pattern of impaired working memory during major depression. J. Affect. Disord. 90(2-3), 149-161 (2006).
61. Fava M, Graves LM, Benazzi F et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J. Clin. Psychiatry 67(11), 1754-1759 (2006). (Pubitemid 44955157)
62. Bornstein RA, Baker GB, Douglass AB. Depression and memory in major depressive disorder. J. Neuropsychiatry Clin. Neurosci. 3(1), 78-80 (1991).
63. Landro NI, Stiles TC, Sletvold H. Neuropsychological function in nonpsychotic unipolar major depression. Neuropsychiatry Neuropsychol. Behav. Neurol. 14(4), 233-240 (2001). (Pubitemid 33051500)
64. Williams RA, Hagerty BM, Cimprich B et al. Changes in directed attention and short-term memory in depression. J. Psychiatr. Res. 34(3), 227-238 (2000). (Pubitemid 30364923)
65. Zakzanis KK, Leach L, Kaplan E. On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry Neuropsychol. Behav. Neurol. 11(3), 111-119 (1998). (Pubitemid 28398675)
66. Caine ED, Yerevanian BI, Bamford KA. Cognitive function and the dexamethasone suppression test in depression. Am. J. Psychiatry 141(1), 116-118 (1984).
67. George MS, Ketter TA, Parekh PI et al. Blunted left cingulate activation in mood disorder subjects during a response interference task (the Stroop). J. Neuropsychiatry Clin. Neurosci. 9(1), 55-63 (1997).
68. Mahurin RK, Velligan DI, Hazleton B et al. Trail making test errors and executive function in schizophrenia and depression. Clin. Neuropsychol. 20(2), 271-288 (2006).
69. Martin DJ, Oren Z, Boone K. Major depressives' and dysthmics' performance on the Wisconsin Card Sorting Test. J. Clin. Psychol. 47(5), 684-690 (1991).
70. Stordal KI, Lundervold AJ, Egeland J et al. Impairment across executive functions in recurrent major depression. Nord. J. Psychiatry 58(1), 41-47 (2004). (Pubitemid 38351195)
71. Trichard C, Martinot JL, Alagille M et al. Time course of prefrontal lobe dysfunction in severely depressed in-patients: a longitudinal neuropsychological study. Psychol. Med. 25(1), 79-85 (1995).
72. Naismith SL, Longley WA, Scott EM, Hickie IB. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry 7, 32 (2007).
73. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 145(1), 39-48 (2006). (Pubitemid 44709192)
74. Paelecke-Habermann Y, Pohl J, Leplow B. Attention and executive functions in remitted major depression patients. J. Affect. Disord. 89(1-3), 125-135 (2005). (Pubitemid 41740840)
75. Lavretsky H, Kim MD, Kumar A, Reynolds CF 3rd. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J. Clin. Psychiatry 64(12), 1410-1414 (2003). (Pubitemid 41270097)
76. Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF 3rd. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am. J. Geriatr. Psychiatry 14(2), 181-185 (2006). (Pubitemid 43227642)
77. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J. Clin. Psychopharmacol. 24(1), 87-90 (2004). (Pubitemid 38134171)
78. Holtzheimer PE III, Meeks TW, Kelley ME et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int. J. Geriatr. Psychiatry 23(6), 625-631 (2008).
79. Pelton GH, Harper OL, Tabert MH et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int. J. Geriatr. Psychiatry 23(7), 670-676 (2008).
80. Perlis RH, Fraguas R, Fava M et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J. Clin. Psychiatry 66(2), 159-166 (2005). (Pubitemid 40314321)
81. Overall JE, Goldstein BJ, Brauzer B. Symptomatic volunteers in psychiatric research. J. Psychiatr. Res. 9(1), 31-43 (1971).
82. Baker M, Dorzab J, Winokur G, Cadoret RJ. Depressive disease: classification and clinical characteristics. Compr. Psychiatry 12(4), 354-365 (1971).
83. Snaith RP, Taylor CM. Irritability: definition, assessment and associated factors. Br. J. Psychiatry 147, 127-136 (1985).
84. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J. Affect. Disord. 85(3), 245-258 (2005). (Pubitemid 40386508)
85. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N. Engl. J. Med. 341(18), 1329-1335 (1999). (Pubitemid 29503571)
86. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch. Gen. Psychiatry 60(1), 39-47 (2003).
87. Silverstein B. Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms. Am. J. Psychiatry 156(3), 480-482 (1999). (Pubitemid 29124176)
88. Husain MM, Rush AJ, Trivedi MH et al. Pain in depression: STAR*D study findings. J. Psychosom. Res. 63(2), 113-122 (2007).
89. Arnold LM, Hudson JI, Keck PE et al. Comorbidity of fibromyalgia and psychiatric disorders. J. Clin. Psychiatry 67(8), 1219-1225 (2006).
90. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. 8(1), 29 (2008).
91. Arnold LM. Management of fibromyalgia and comorbid psychiatric disorders. J. Clin. Psychiatry 69(Suppl. 2), 14-19 (2008).
92. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr. Opin. Anaesthesiol. 20(5), 456-472 (2007). (Pubitemid 47415136)
93. Rush AJ. STAR*D: what have we learned? Am. J. Psychiatry 164(2), 201-204 (2007).
94. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 88(Suppl. 2), S61-S71 (2007).
95. Segal Z, Vincent P, Levitt A. Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression. J. Psychiatry Neurosci. 27(4), 281-290 (2002). (Pubitemid 34988908)
96. Trivedi MH, Kurian BT, Grannemann BD. Clinical predictors in major depressive disorder. Prim. Psychiatry 14(6), 47-53 (2007).
97. Pandi-Perumal SR, Trakht I, Srinivasan V et al. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J. Biol. Psychiatry 1-13 (2008).
98. Anderson AD, Oquendo MA, Parsey RV et al. Regional brain responses to serotonin in major depressive disorder. J. Affect. Disord. 82(3), 411-417 (2004).
99. Lekman M, Laje G, Charney D et al. The FKBP5-gene in depression and treatment response - an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol. Psychiatry 63(12), 1103-1110 (2008).
100. Lin E, Chen PS. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 9(7), 935-946 (2008).
101. Paddock S, Laje G, Charney D et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am. J. Psychiatry 164(8), 1181-1188 (2007). (Pubitemid 47292406)
102. Perlis RH, Moorjani P, Fagerness J et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 33, 2810-2819 (2008).